Toshiki Masuishi

phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study

Background Trifluridine/tipiracil (FTD/TPI) showed survival benefit as monotherapy and in combination with bevacizumab (BEV) in the la...

K. Yamazaki ;

Toshiki Masuishi ;

T. Tsushima ;

K. Muro ;

H. Yasui ;

Kazuki Mori , MD;

H. Taniguchi ;

07/01/2019

Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study

Background Treatment of refractory metastatic colorectal cancer (mCRC) with trifluridine/tipiracil yields some survival benefits. Trifluridine/tipiracil combined with be...

S. Hamauchi ;

K. Yamazaki ;

Toshiki Masuishi ;

T. Tsushima ;

K. Muro ;

H. Yasui ;

Kazuki Mori , MD;

H. Taniguchi ;

T. Kawakami ;

Y. Onozawa ;

K. Honda ;

06/27/2022

Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study

BackgroundVascular endothelial growth factor (VEGF)-D high have been reported as a negative prognostic marker and potential predictive marker for ramucirumab (RAM) efficacy in metastatic ...

Toshiki Masuishi ;

H. Kawakami ;

T. Tsushima ;

S. Hironaka ;

K. Muro ;

K. Shimozaki ;

H. Yasui ;

T. Esaki ;

Y. Kito ;

K. Sakai ;

K. Nishio ;

H. Shoji ;